. 2023 Oct 11;81(1):77–88. doi: 10.1001/jamapsychiatry.2023.3850

Table. Characteristics of the Sample at Clinical High Risk for Psychosis.

Characteristic	Participants
All individuals with CHR-P (n = 1340)
Age, mean (SD), y	20.75 (4.74)
Sex, No. (%)
Female	631 (47.09)
Male	709 (52.91)
SIPS positive symptoms score, mean (SD)^a^,^b	10.93 (4.66)
CAARMS positive symptoms score, mean (SD)^a^,^c	10.37 (4.03)
IQ, mean (SD) z score^d	−0.21 (1.00)
Prescribed antipsychotic medication, No. (%)^e	243 (18.63)
Follow-up, mean (SD), mo^f	19.71 (13.97)
Individuals who converted to a psychotic disorder, No. (%)^f	157 (14.31)
Individuals with CHR-P who converted to a psychotic disorder (n = 157)
Age, mean (SD), y	20.09 (4.68)
Sex, No. (%)
Female	64 (40.76)
Male	93 (59.24)
SIPS positive symptoms score, mean (SD)^g	12.12 (5.06)
CAARMS positive symptoms score, mean (SD)^h	10.71 (4.24)
IQ, mean (SD) z scoreⁱ	−0.29 (1.03)
Prescribed antipsychotic medication, No. (%)^j	32 (20.38)

Abbreviations: CAARMS, Comprehensive Assessment of At-Risk Mental States; CHR-P, clinical high risk for psychosis; SIPS, Structured Interview for Psychosis-Risk Syndromes.

^{^a}

Positive symptom ratings at the time of scanning were available for the entire sample of individuals with CHR-P (n = 1340), assessed either with the SIPS or the CAARMS.

^{^b}

The SIPS was used to assess positive symptoms in 806 participants with CHR-P.

^{^c}

The CAARMS was used to assess positive symptoms in 534 participants with CHR-P.

^{^d}

Estimates of IQ were available for 924 participants with CHR-P; z scores were used to accommodate site differences in the instruments used (eTable 1 in Supplement 1).

^{^e}

Medication status at the time of scanning was available for 1304 individuals with CHR-P.

^{^f}

Conversion status was known for 1097 participants with CHR-P, but information about the length of the follow-up period was available for only 975 individuals with CHR-P.

^{^g}

The SIPS was used to assess 115 individuals with CHR-P who converted to a psychotic disorder.

^{^h}

The CAARMS was used to assess 42 individuals with CHR-P who converted to a psychotic disorder.

^ⁱ

Estimates of IQ were available for 109 individuals with CHR-P who converted to a psychotic disorder.

^{^j}

Medication status was available for 157 individuals with CHR-P who converted to a psychotic disorder.